ONKOSXCEL THERAPEUTICS
Live / Applied — Fifth extension granted (statement of use) (as of 15 Dec 2025)
What this means for you
Not registered yet, but its 18 Mar 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97319590
- Mark type
- Stylized text
- Filed
- 18 Mar 2022
- Published for opposition
- 25 Apr 2023
- Attorney of record
- Brendan J. Hughes
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals and biopharmaceuticals in the nature of preparations for the treatment of oncology diseases; pharmaceuticals and biopharmaceuticals in the nature of preparations for the treatment of immuno-oncology diseases; pharmaceuticals and biopharmaceuticals in the nature of preparations for the treatment of cancer, tumor, prostate cancer, castration resistant prostate cancer, neuro endocrine tumors, small cell neuroendocrine cancer, small cell lung cancer, adenocarcinoma, melanoma, sarcoma, soft tissue sarcoma, acute myeloid leukemia, head and neck cancers, pancreatic cancer, neuroendocrine prostate cancer
Owner
- OnkosXcel Therapeutics, LLC, New Haven, CT, US
- OnkosXcel Therapeutics, LLC, New Haven, CT, US
Prosecution history
- 15 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Dec 2025 — SOU EXTENSION 5 GRANTED
- 02 Dec 2025 — SOU EXTENSION 5 FILED
- 03 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 May 2025 — SOU EXTENSION 4 GRANTED
- 28 May 2025 — SOU EXTENSION 4 FILED
- 28 May 2025 — SOU TEAS EXTENSION RECEIVED
- 05 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Dec 2024 — SOU EXTENSION 3 GRANTED
- 05 Dec 2024 — SOU EXTENSION 3 FILED
- 05 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 13 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Jun 2024 — SOU EXTENSION 2 GRANTED
- 10 Jun 2024 — SOU EXTENSION 2 FILED